For ValueAct, There is Life After Valeant

January 31, 2018   Stephen Taub

The activist hedge fund’s 2017 performance was buoyed by a large position in Twenty-First Century Fox.

ValueAct Capital continues to thrive despite holding onto Valeant Pharmaceuticals, the troubled drug company whose stock crashed spectacularly in the fall of 2015, and hasn’t recovered since. The activist and value investor posted a 7 percent gain in the fourth …


Subscribers have unlimited access to all online content inc rankings. Start your subscription today - click on the button below.

Subscribe now

Free trial

Taking a free trial will give you access to online content one week (excludes research & rankings). Start your trial today.

Free Trial

Latest Poll

How will hedge funds finish 2017?

 - 72%
 - 10%
 - 17%

View previous results